Equillium (EQ) Projected to Post Earnings on Wednesday

Key Points

• Equillium will report Q1 2026 results after the market close on May 13, 2026; analysts are forecasting EPS of ($0.04) and the company has an earnings call scheduled for May 12 at 4:00 PM ET.
• Wall Street coverage is largely positive with a consensus rating of Moderate Buy and a consensus target of $7.67, well above the current share price (~$2.07), as multiple firms initiated Buy/Strong-Buy ratings with $5–$10 targets.
• Insider activity shows notable selling — the COO sold 185,937 shares and insiders have sold 487,468 shares (~$990,467) in the last three months — while insiders hold 17.84% and institutional investors own 27.05% of the stock.

Equillium (NASDAQ:EQ - Get Free Report) will likely be posting its Q1 2026 results after the market closes on Wednesday, May 13th. Analysts expect Equillium to post earnings of ($0.04) per share for the quarter. Interested persons are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:00 PM ET.

Equillium (NASDAQ:EQ - Get Free Report) last released its quarterly earnings data on Wednesday, March 25th. The company reported ($0.04) EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.03. On average, analysts expect Equillium to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Equillium Price Performance

EQ stock opened at $2.07 on Wednesday. The company has a fifty day moving average price of $1.99 and a two-hundred day moving average price of $1.52. Equillium has a one year low of $0.27 and a one year high of $2.70. The stock has a market cap of $130.89 million, a price-to-earnings ratio of -4.14 and a beta of 1.67.

Wall Street Analysts Forecast Growth

A number of research firms have commented on EQ. Raymond James Financial began coverage on shares of Equillium in a research report on Monday, April 13th. They set a "strong-buy" rating and a $6.00 price objective for the company. Stifel Nicolaus began coverage on shares of Equillium in a research report on Wednesday, February 25th. They set a "buy" rating and a $5.00 price objective for the company. Zacks Research raised shares of Equillium to a "hold" rating in a research report on Thursday, February 26th. Oppenheimer began coverage on shares of Equillium in a research report on Thursday, April 23rd. They set an "outperform" rating and a $7.00 price objective for the company. Finally, Cantor Fitzgerald began coverage on shares of Equillium in a research report on Tuesday, April 7th. They set an "overweight" rating and a $10.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Equillium currently has a consensus rating of "Moderate Buy" and a consensus target price of $7.67.

Insider Buying and Selling

In related news, COO Christine Zedelmayer sold 185,937 shares of the business's stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $1.76, for a total value of $327,249.12. Following the completion of the transaction, the chief operating officer owned 191,444 shares of the company's stock, valued at $336,941.44. The trade was a 49.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders sold a total of 487,468 shares of company stock valued at $990,467 over the last three months. 17.84% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of EQ. Vanguard Group Inc. raised its stake in Equillium by 59.4% in the third quarter. Vanguard Group Inc. now owns 1,313,946 shares of the company's stock valued at $1,879,000 after purchasing an additional 489,855 shares in the last quarter. Two Sigma Investments LP acquired a new position in Equillium in the third quarter valued at about $190,000. ADAR1 Capital Management LLC acquired a new position in Equillium in the third quarter valued at about $7,951,000. Virtu Financial LLC raised its stake in Equillium by 133.4% in the third quarter. Virtu Financial LLC now owns 23,779 shares of the company's stock valued at $34,000 after purchasing an additional 13,591 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC acquired a new position in Equillium in the third quarter valued at about $178,000. Institutional investors and hedge funds own 27.05% of the company's stock.

Equillium Company Profile

Equillium, Inc NASDAQ: EQ is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company's lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium's pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody's established safety profile in earlier clinical studies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.